Kristina Johnson, 25, is undergoing treatment for a very rare and aggressive brain tumor. Her response to the experimental drug has been “amazing,” according to her oncologist at Dana-Farber, Patrick Wen, MD. And while her response is not that of an average brain tumor patient, doctors say it represents a step forward for patients with this rare cancer.
When Kerry Evers’ cousin with colon cancer learned he had inherited a mutation in one of these genes (MLH1), he recommended everyone in the family undergo genetic testing. After testing, Evers confirmed that she too had the MLH1 gene mutation. A decade later, Evers still does not have cancer—but thanks to ongoing care from her team, now situated within the new Lynch Syndrome Center at Dana-Farber, she understands her situation and her options.
Sign up to subscribe to any of our e-newsletters or digital content.
